Mesothelioma: Time to take stock

Journal of the Royal Society of Medicine

Volumn 98, Issue 10, 2005, Pages 455-458

  Tan, Carol ^a   Treasure, Tom ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASBESTOS; CISPLATIN; DOXORUBICIN; PEMETREXED;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG RESISTANCE; HISTOPATHOLOGY; HUMAN; MESOTHELIOMA; PLEURODESIS; REVIEW;

EID: 27144548037     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.98.10.455     Document Type: Review

References (25)

1. Health and Safety Executive. Mesothelioma. [www.hse.gov.uk/statistics/ causdis/meso.htm]
2. Toms JR, ed. CancerStats Monograph 2004. London: Cancer Research UK, 2004
3. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92:587-93
4. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72
5. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345:535-9
6. [www.legislation.hmso.gov.uk] 2005
7. LaDou J, Landrigan P, Bailar JC, III, Foa V, Frank A. A call for an international ban on asbestos. Can Med Assoc J 2001;164:489-90
8. Guidotti TL. The debate on banning asbestos. Can Med Assoc J 2001;165:1189-90
9. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976;31:15-24
10. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet 2004;364:1183-5
11. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22:3451-7
12. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998;113(1 suppl):66S-73S
13. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38:111-21
14. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44
15. Armato SG, III, Oxnard GR, MacMahon H, et al. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys 2004;31:1105-15
16. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995;108:754-8
17. Graaf-Strukowska L, van der ZJ, van Putten W, Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura-a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999;43:511-16
18. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-95
19. Forster KM, Smythe WR, Starkschall G et al. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys 2003;55:606-16
20. Soysal O, Karaoglanoglu N, Demiracan S, et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur J Cardiothorac Surg 1997;11:210-13
21. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63
22. Tan C, Swift S, Gilham C, Shaefi S, et al. Survival in surgically diagnosed patients with malignant mesothelioma in current practice. Thorax 2002;57:iii36
23. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 2002;22:298-305
24. Stephens R. The dangers of subgroup analysis. Lancet Oncol 2001;2:9
25. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-16